Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus

Repros Therapeutics Inc. RPRX reported a loss of 20 cents per share in the first quarter of 2016, significantly narrower than the year-ago loss of 35 cents mainly due to lower research & development (R&D) expenses. First-quarter revenues (interest income) increased to $17,000 from $1,000 in the year-ago period.

R&D costs decreased 48.6% year over year to $3.8 million reflecting lower development expenses related to the enclomiphene product candidate, R&D payroll and benefits expenses and legal expenses, partially offset by higher development expenses related to Proellex. General and administrative expenses also decreased 9% year over year to $1.1 million.

Proellex is being evaluated for uterine fibroids and endometriosis.

Enclomiphene, which was issued a complete response letter (CRL) by the FDA in late 2015, is being developed for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Repros is currently conducting a phase II double-blind, placebo controlled, proof of concept study (ZA-205), in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. Six month data is expected in the third quarter of 2016.
 
Considering that Repros has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.

Repros is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the health care sector are Apricus Biosciences, Inc. APRI, ArQule Inc. ARQL and BioSpecifics Technologies Corp. BSTC. All three carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. http://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&... blog">Click to get this free report >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
REPROS THERAPEU (RPRX): Free Stock Analysis Report
 
BIOSPECIFICS TE (BSTC): Free Stock Analysis Report
 
APPRICUS BIOSCI (APRI): Free Stock Analysis Report
 
ARQULE INC (ARQL): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research